PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment

被引：0
|
作者：
Gaëtan Devos
Steven Joniau
机构：
[1] University Hospitals Leuven,Department of Urology
来源：
BMC Medicine | / 18卷
关键词：
Prostate cancer; Prognosis; Prostate cancer-specific mortality; Decision aid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
    Devos, Gaetan
    Joniau, Steven
    [J]. BMC MEDICINE, 2020, 18 (01)
  • [2] Management of low- and intermediate-risk prostate cancer
    Henk van der Poel
    Laurence Klotz
    Christian G. Stief
    [J]. World Journal of Urology, 2015, 33 : 905 - 906
  • [3] Management of low- and intermediate-risk prostate cancer
    van der Poel, Henk
    Klotz, Laurence
    Stief, Christian G.
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 905 - 906
  • [4] Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance
    Courtney, P. Travis
    Deka, Rishi
    Kotha, Nikhil, V
    Cherry, Daniel R.
    Salans, Mia A.
    Nelson, Tyler J.
    Kumar, Abhishek
    Luterstein, Elaine
    Yip, Anthony T.
    Nalawade, Vinit
    Parsons, J. Kellogg
    Kader, A. Karim
    Stewart, Tyler F.
    Rose, Brent S.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02): : 151 - +
  • [5] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Cyll, Karolina
    Loffeler, Sven
    Carlsen, Birgitte
    Skogstad, Karin
    Plathan, May Lisbeth
    Landquist, Martin
    Haug, Erik Skaaheim
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Karolina Cyll
    Sven Löffeler
    Birgitte Carlsen
    Karin Skogstad
    May Lisbeth Plathan
    Martin Landquist
    Erik Skaaheim Haug
    [J]. Scientific Reports, 12
  • [7] Longitudinal regret after treatment for low- and intermediate-risk prostate cancer
    Hurwitz, Lauren M.
    Cullen, Jennifer
    Kim, Daniel J.
    Elsamanoudi, Sally
    Hudak, Jane
    Colston, Maryellen
    Travis, Judith
    Kuo, Huai-Ching
    Rice, Kevin R.
    Porter, Christopher R.
    Rosner, Inger L.
    [J]. CANCER, 2017, 123 (21) : 4252 - 4258
  • [8] Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
    Stephens, R.
    Gopaul, D.
    Panjwani, D.
    Lock, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S732 - S732
  • [9] Personalizing the Management of Men with Intermediate-risk Prostate Cancer
    D'Amico, Anthony V.
    [J]. EUROPEAN UROLOGY, 2013, 64 (06) : 903 - 904
  • [10] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
12345